Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:ASRT NYSE:DNA NASDAQ:IMMX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.93-2.0%$2.91$2.56▼$6.44$581.48M0.254.62 million shs3.29 million shsASRTAssertio$23.50$23.35$8.61▼$23.50$151.81M0.52271,083 shsN/ADNAGinkgo Bioworks$9.07+0.2%$8.92$5.37▼$17.58$591.19M1.771.10 million shs702,011 shsIMMXImmix Biopharma$10.68+1.5%$9.46$1.94▼$12.14$572.41M0.092.31 million shs1.19 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.01%-2.98%+12.26%-13.82%-31.22%ASRTAssertio0.00%0.00%+0.09%+30.41%+128.48%DNAGinkgo Bioworks-0.11%-3.31%+15.14%+16.29%-8.56%IMMXImmix Biopharma+1.52%-11.15%+26.39%+6.37%+269.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.93-2.0%$2.91$2.56▼$6.44$581.48M0.254.62 million shs3.29 million shsASRTAssertio$23.50$23.35$8.61▼$23.50$151.81M0.52271,083 shsN/ADNAGinkgo Bioworks$9.07+0.2%$8.92$5.37▼$17.58$591.19M1.771.10 million shs702,011 shsIMMXImmix Biopharma$10.68+1.5%$9.46$1.94▼$12.14$572.41M0.092.31 million shs1.19 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.01%-2.98%+12.26%-13.82%-31.22%ASRTAssertio0.00%0.00%+0.09%+30.41%+128.48%DNAGinkgo Bioworks-0.11%-3.31%+15.14%+16.29%-8.56%IMMXImmix Biopharma+1.52%-11.15%+26.39%+6.37%+269.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.70Moderate Buy$15.71436.32% UpsideASRTAssertio 1.80Reduce$22.65-3.62% DownsideDNAGinkgo Bioworks 1.67Reduce$8.50-6.23% DownsideIMMXImmix Biopharma 2.67Moderate Buy$20.6793.51% UpsideCurrent Analyst Ratings BreakdownLatest ASRT, DNA, IMMX, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/22/2026ALTAltimmune Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/18/2026IMMXImmix Biopharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/18/2026IMMXImmix Biopharma Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.006/17/2026IMMXImmix Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$19.006/2/2026ALTAltimmune CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/22/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.005/13/2026ASRTAssertio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$21.80 ➝ $23.505/5/2026ASRTAssertio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $21.80(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K14,244.93N/AN/A$1.99 per share1.47ASRTAssertio$118.71M1.28$0.02 per share1,437.29$14.63 per share1.61DNAGinkgo Bioworks$170.15M3.48N/AN/A$8.74 per share1.04IMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)ASRTAssertio-$30.38M-$5.69N/A21.17N/A-34.94%-38.72%-13.32%7/30/2026 (Estimated)DNAGinkgo Bioworks-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)IMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%8/14/2026 (Estimated)Latest ASRT, DNA, IMMX, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ALTAltimmune-$0.15N/AN/AN/A$0.00 millionN/A8/10/2026Q2 2026ASRTAssertio-$0.07N/AN/AN/A$27.66 millionN/A8/6/2026Q2 2026DNAGinkgo Bioworks-$0.91N/AN/AN/A$24.85 millionN/A5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/8/2026Q1 2026ASRTAssertio-$2.1025-$2.93-$0.8275-$2.93$8.97 million$9.93 million5/7/2026Q1 2026DNAGinkgo Bioworks-$1.2112-$1.39-$0.1789-$1.39$42.93 million$19.00 million5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AASRTAssertioN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56ASRTAssertio0.521.821.57DNAGinkgo BioworksN/A5.155.15IMMXImmix BiopharmaN/A8.758.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%ASRTAssertio48.96%DNAGinkgo Bioworks78.63%IMMXImmix Biopharma11.26%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%ASRTAssertio5.70%DNAGinkgo Bioworks12.69%IMMXImmix Biopharma30.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableASRTAssertio206.46 million6.09 millionOptionableDNAGinkgo Bioworks64065.32 million57.03 millionOptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableASRT, DNA, IMMX, and ALT HeadlinesRecent News About These CompaniesLGT Fund Management Co Ltd. Acquires 291,594 Shares of Immix Biopharma, Inc. $IMMXJuly 13 at 5:43 AM | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 12 at 6:13 PM | marketbeat.comWhy Immix Biopharma, Inc.’s (IMMX) Stock Is Up 10.10%July 7, 2026 | aaii.comAAll You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to BuyJune 24, 2026 | zacks.comLifesci Capital Estimates Immix Biopharma Q2 EarningsJune 19, 2026 | marketbeat.comWall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a BetJune 18, 2026 | zacks.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)May 28, 2026 | theglobeandmail.comWall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?May 27, 2026 | zacks.comImmix Biopharma, Inc. Closes $140.65 Million Underwritten Registered Offering of Common StockMay 22, 2026 | quiverquant.comQImmix Biopharma Announces Closing of $150 Million Underwritten Offering of Common StockMay 22, 2026 | globenewswire.comImmix rises after mid-stage trial data for AL amyloidosis therapyMay 21, 2026 | seekingalpha.comWhat's going on with Immix Biopharma stock Thursday?May 21, 2026 | msn.comImmix Biopharma Reports 95% Complete Response Rate in NEXICART-2 Trial for AL Amyloidosis PatientsMay 21, 2026 | quiverquant.comQImmix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common StockMay 21, 2026 | globenewswire.comImmix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2May 21, 2026 | globenewswire.comIs Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?May 5, 2026 | finance.yahoo.comImmix Biopharma (IMMX) price target increased by 11.73% to 18.62April 9, 2026 | msn.comImmix Biopharma to Participate in the Jefferies Global Healthcare ConferenceApril 9, 2026 | globenewswire.comImmix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming MilestonesMarch 30, 2026 | globenewswire.comMorgan Stanley initiates coverage of Immix Biopharma (IMMX) with overweight recommendationMarch 25, 2026 | msn.comImmix rises as Morgan Stanley starts with bullish view on CAR-T therapyMarch 25, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASRT, DNA, IMMX, and ALT Company DescriptionsAltimmune NASDAQ:ALT$2.93 -0.06 (-2.01%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$2.94 +0.01 (+0.51%) As of 07:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Assertio NASDAQ:ASRT$23.50 0.00 (0.00%) As of 06/17/2026Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Ginkgo Bioworks NYSE:DNA$9.06 +0.02 (+0.17%) Closing price 07/14/2026 03:59 PM EasternExtended Trading$9.05 -0.02 (-0.21%) As of 07:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Immix Biopharma NASDAQ:IMMX$10.68 +0.16 (+1.52%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$10.68 0.00 (0.00%) As of 06:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
